Microbix Honours the Passing of its Founder William J. Gastle – 1948 to 2023
By Microbix Admin | September 13, 2023Microbix Reports Results for Q3 Fiscal 2023
By Microbix Admin | August 10, 2023Microbix Successfully Upgrades Logistics Software Systems
By Microbix Admin | August 7, 2023Microbix Presents Results of STI Test Controls at AACC
By Microbix Admin | July 24, 2023Microbix QAPs Supporting HPV Testing Across The Netherlands
By Microbix Admin | July 5, 2023Microbix & Labquality Create Novel Testing Accreditation Program
By Microbix Admin | June 20, 2023Microbix Presents Results of STI Test Controls at ASM Microbe
By Pavel Zhelev | June 13, 2023
Microbix Announces Extension of Warrant Expiry Date
By Pavel Zhelev | May 19, 2023Microbix Secures Funded Drug Commercialization Agreement
By Microbix Admin | May 16, 2023Microbix Reports Results for Q2 Fiscal 2023
By Microbix Admin | May 11, 2023Microbix Presenting at the 2023 Bloom Burton Conference
By Pavel Zhelev | April 20, 2023
Microbix Announces Annual and Special Meeting Voting Results
By Pavel Zhelev | March 30, 2023
Microbix Annual General Meeting (AGM) Update
By shitika | March 22, 2023
Governments of Ontario and Canada Invest in Microbix
By Pavel Zhelev | March 20, 2023
Microbix Supporting Australian Point-of-Care Testing Program
By Pavel Zhelev | March 1, 2023
Microbix Announces Issuance of Stock Options
By shitika | February 27, 2023
Microbix Reports Results for Q1 Fiscal 2023
By Pavel Zhelev | February 9, 2023
Microbix Presenting Results of Collaboration with Health PEI
By Pavel Zhelev | February 6, 2023
Microbix Launches QAP to Support “Monkeypox” Testing
By Pavel Zhelev | January 30, 2023
Microbix Reports Record Sales for Fiscal 2022
By Pavel Zhelev | December 22, 2022
Microbix Presenting Test-Workflow Validation Results at EMMD
By Pavel Zhelev | October 6, 2022
Microbix Announces Initiation of Normal Course Issuer Bid
By Pavel Zhelev | September 28, 2022
Microbix Presenting at Muskoka Capital Conference
By Pavel Zhelev | September 21, 2022
Microbix Reports Results for Q3 Fiscal 2022
By Pavel Zhelev | August 12, 2022
Microbix Executes Substantial QAPs Supply Agreement
By Pavel Zhelev | August 10, 2022Microbix Presenting STI Multiplex Test Controls at AACC
By Pavel Zhelev | July 26, 2022
Microbix Presenting Test Validation Methods at AACC
By Pavel Zhelev | June 3, 2022
Microbix Reports Record Results for Q2 Fiscal 2022
By Pavel Zhelev | May 12, 2022
Microbix Presenting Omicron Test Control Results at CVS
By Pavel Zhelev | April 29, 2022
Microbix Presenting at the 2022 Bloom Burton Conference
By Pavel Zhelev | April 28, 2022
Microbix Presenting Respiratory Virus Controls Data at Two Events
By Pavel Zhelev | April 19, 2022
Microbix Presenting HPV Product Results at EUROGIN
By Pavel Zhelev | April 8, 2022
Microbix Announces Annual and Special Meeting Voting Results
By Pavel Zhelev | March 31, 2022
Microbix Invests to Further Scale Its Business
By Pavel Zhelev | March 29, 2022
Microbix Announces Issuance of Stock Options
By Pavel Zhelev | February 24, 2022
Microbix Announces Nomination to Board of Directors
By Pavel Zhelev | February 22, 2022
Microbix Presenting at Capital Conference in B.C.
By Pavel Zhelev | February 17, 2022
Microbix Advances Commissioning of Sites Two and Three
By Pavel Zhelev | February 15, 2022
Microbix Reports Record Results for Q1 Fiscal 2022
By Pavel Zhelev | February 10, 2022
Microbix Launches Omicron Variant Test Control
By Pavel Zhelev | February 1, 2022
Microbix Receives $4.7 Million Order for Viral Transport Medium
By Pavel Zhelev | December 24, 2021
Microbix Reports Record Results for Fiscal 2021
By Pavel Zhelev | December 23, 2021
Microbix Launches Multiplex Respiratory PCR-Test Control
By Pavel Zhelev | December 20, 2021
Microbix Expands Pandemic Test Controls (QAPs™) Portfolio
By Pavel Zhelev | November 17, 2021
Microbix Receives $2.7 Million from Exercise of Warrants
By Pavel Zhelev | October 27, 2021
Microbix Makes Early Repayment of 9% Interest Debenture
By Pavel Zhelev | October 4, 2021
Microbix Presenting Product Results at AACC
By Pavel Zhelev | September 27, 2021
Microbix Reports Record Results for Q3 Fiscal 2021
By Pavel Zhelev | August 12, 2021
Microbix Upgrades U.S. OTC Market & Investor Relations
By Pavel Zhelev | August 3, 2021
Microbix Presenting Product Results to Industry
By Pavel Zhelev | July 8, 2021
Microbix Announces Quality Products Distribution Agreement
By Pavel Zhelev | July 7, 2021
Microbix Secures Third Ontario Manufacturing Site
By Pavel Zhelev | June 3, 2021
Microbix Announces Quality Products Distribution Agreement
By Pavel Zhelev | May 31, 2021
Microbix Announces Closing of Offering and Private Placement
By Pavel Zhelev | May 19, 2021
Microbix Reports Record Results for Q2 Fiscal 2021
By Pavel Zhelev | May 13, 2021
Microbix Announces $6.0 Million of Financings
By Pavel Zhelev | April 28, 2021
Microbix & SpeeDx Form Exclusive Collaboration
By Pavel Zhelev | April 26, 2021
Microbix Receives $4.25 Million Order For Viral Transport Medium
By Pavel Zhelev | April 23, 2021
Microbix Announces Annual and Special Meeting Voting Results
By Pavel Zhelev | March 31, 2021
Microbix & Seegene Canada Form COVID-Variant Collaboration
By Pavel Zhelev | March 15, 2021
Microbix Antigen-test QAPs Now Available For Clinical Use
By Pavel Zhelev | March 11, 2021
Microbix Announces Issuance of Stock Options
By Pavel Zhelev | February 18, 2021
Microbix Announces Quality Products Distribution Agreement
By Pavel Zhelev | February 16, 2021
Microbix Reports Results for Q1 Fiscal 2021
By Pavel Zhelev | February 11, 2021
Microbix Announces Material First Sales of Viral Transport Medium
By Pavel Zhelev | February 9, 2021
Microbix Viral Transport Medium Now Available
By Pavel Zhelev | January 28, 2021
Microbix & Copan Italia Execute Strategic Agreement
By Pavel Zhelev | December 21, 2020
Microbix Reports Results for Fiscal 2020
By Pavel Zhelev | December 18, 2020
Microbix Presenting Product Results at AACC
By Pavel Zhelev | December 15, 2020
Microbix Announces Addition to Board of Directors
By Pavel Zhelev | December 7, 2020
Microbix Discloses New Products, Sales, And Capacity
By Microbix Admin | October 29, 2020
Microbix Creates Further COVID-19 Quality Assessment Products
By Microbix Admin | October 20, 2020
Ontario Helps Microbix Ensure Provincial COVID Testing Capacity
By Microbix Admin | October 13, 2020
Microbix Presenting COVID-19 Product Results To Industry
By Microbix Admin | September 22, 2020
Microbix Announces Extension Of Warrant Expiry Dates
By Microbix Admin | September 17, 2020
Microbix Announces Board Changes
By Microbix Admin | September 15, 2020
Microbix’s REDx™ Controls Attain Australian TGA Registration
By Microbix Admin | September 10, 2020
Q3 Fiscal 2020
By Microbix Admin | August 14, 2020
Microbix Shares Become Available For U.S. Investors
By Microbix Admin | July 14, 2020
Microbix COVID-19 QAPs Attain EU “CE Mark” Registration
By Microbix Admin | June 5, 2020
Microbix Announces Quality Products Distribution Agreement
By Microbix Admin | June 4, 2020
Microbix Engaged To Develop & Supply Custom QAPs™
By Microbix Admin | June 2, 2020
Microbix Expanding QAPs™ Production Capacity
By Microbix Admin | May 27, 2020
Microbix Achieves Full Utilization Of Its Bioreactors
By Microbix Admin | May 19, 2020
Microbix Announces Quality Products Distribution Agreement
By Microbix Admin | May 15, 2020
Microbix Reports Record Second Quarter Sales
By Microbix Admin | May 14, 2020Microbix Reports Results For Q2 Fiscal 2020
By Microbix Admin | May 14, 2020
Microbix Announces Quality Products Distribution Agreement
By Microbix Admin | May 12, 2020
Microbix COVID-19 QAPs Now Available for U.S. Labs
By Microbix Admin | May 7, 2020Microbix Begins Providing COVID-19 Test Quality Products
By Microbix Admin | May 6, 2020
Microbix Announces Quality Products Distribution Agreement
By Microbix Admin | April 27, 2020
Microbix Attains Health Canada Establishment Licensing
By Microbix Admin | April 21, 2020
Microbix & Oneworld Create COVID-19 Test Quality Program
By Microbix Admin | April 9, 2020
Microbix Announces Annual And Special Meeting Voting Results
By Microbix Admin | April 1, 2020
Microbix Creates Quality Assessment Product For COVID-19 Tests
By Microbix Admin | March 30, 2020
Microbix Annual General Meeting Process Update
By Microbix Admin | March 25, 2020
Microbix Announces Quality Products Distribution Agreement
By Microbix Admin | March 24, 2020
Microbix Announces Issuance Of Stock Options
By Microbix Admin | February 25, 2020
Microbix Reports Results For Q1 Fiscal 2020
By Microbix Admin | February 13, 2020
Microbix Completes Non-Brokered Private Placement Of $2.3 Million
By Microbix Admin | January 31, 2020